Citigroup
AIM

Citigroup’s AIM ImmunoTech AIM Stock Holding History

Citigroup’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9
Closed -$171 – 6124
2024
Q4 		$171 Buy
+9
New +$210 ﹤0.01% 5669
2021
Q2 		– Sell
-1
Closed – – 6654
2021
Q1 		$0 Hold
1
– – ﹤0.01% 7934
2020
Q4 		$0 Hold
1
– – ﹤0.01% 7861
2020
Q3 		$0 Hold
1
– – ﹤0.01% 7807
2020
Q2 		$0 Hold
1
– – ﹤0.01% 7908
2020
Q1 		$0 Buy
+1
New +$157 ﹤0.01% 8003
2016
Q2 		– Hold
0
– – – 8007
2016
Q1 		– Hold
0
– – – 8300
2014
Q2 		– Sell
-1
Closed -$14K – 7725
2014
Q1 		$14K Buy
+1
New +$21.2K ﹤0.01% 6224
2013
Q4 		– Hold
0
– – – 7525
2013
Q3 		– Hold
0
– – – 7369
2013
Q2 		– Hold
0
– – – 6721

Other funds holding AIM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Citigroup's AIM Position: Q1 2025 in Review

Citigroup sold out of AIM ImmunoTech (AIM) in Q1 2025, closing a stake of 9 shares — an estimated $171 sold.

Citigroup first reported a position in AIM in Q1 2014 and held it in 7 quarters. The position peaked at $14K in Q1 2014. 32 funds tracked by Wall St. Rank hold AIM as of Q1 2025.

  • Citigroup reported no remaining AIM ImmunoTech position as of Q1 2025 after selling out during the quarter.
  • Citigroup sold 9 AIM ImmunoTech shares in Q1 2025, an estimated $171.
  • Citigroup first reported a position in AIM ImmunoTech in Q1 2014 and held it in 7 quarters.
  • Citigroup's AIM ImmunoTech position peaked at $14K in Q1 2014.
  • 32 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q1 2025.

Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.